CGRP (Calcitonin Gene-Related Peptide) Dosage Calculator

CGRP (Calcitonin Gene-Related Peptide) Pharmacokinetics

CGRP (Calcitonin Gene-Related Peptide) Dosing Protocol

Note: CGRP (Calcitonin Gene-Related Peptide) is a 37-amino-acid neuropeptide existing as two isoforms: alpha-CGRP (encoded by the CALCA gene via alternative splicing of calcitonin mRNA) and beta-CGRP (encoded by the separate CALCB gene). Alpha-CGRP predominates in the central and peripheral nervous system, while beta-CGRP is found primarily in the enteric nervous system. CGRP is the most potent endogenous vasodilator known, approximately 1,000 times more potent than acetylcholine and 10 times more potent than prostaglandins on a molar basis. It is widely distributed in sensory C-fibers and A-delta fibers of trigeminal and dorsal root ganglia. CGRP became the central therapeutic target in migraine after the landmark discovery that serum CGRP levels are elevated during migraine attacks and that intravenous CGRP infusion triggers migraine-like headache in susceptible individuals. This led to the development of anti-CGRP monoclonal antibodies (erenumab targeting the CGRP receptor; fremanezumab, galcanezumab, and eptinezumab targeting the CGRP ligand) and small-molecule CGRP receptor antagonists (gepants: ubrogepant, rimegepant, atogepant), all FDA-approved for migraine prevention or acute treatment. The CGRP peptide itself remains a research-only compound with no approved therapeutic indication. Exogenous CGRP administration has been investigated in preclinical and early clinical studies for wound healing, cardioprotection, and vascular conditions, but development has been limited by its extremely short half-life, potent hypotensive effects, and flushing. Dosing values shown are derived from intravenous infusion studies in human volunteers and should not be interpreted as therapeutic dosing guidance. CGRP carries significant cardiovascular risks at higher doses and should only be handled in controlled research environments with hemodynamic monitoring.

About CGRP (Calcitonin Gene-Related Peptide)

Calcitonin Gene-Related Peptide (CGRP) is a 37-amino-acid neuropeptide first identified in 1982 by Amara and colleagues through analysis of alternative RNA processing of the calcitonin gene (CALCA). It exists as two isoforms: alpha-CGRP, produced by alternative splicing of calcitonin mRNA predominantly in sensory neurons, and beta-CGRP, encoded by a separate gene (CALCB) with 94% homology, expressed primarily in enteric neurons. Alpha-CGRP is one of the most abundant neuropeptides in the human body and the most widely studied isoform. CGRP belongs to the calcitonin peptide family alongside calcitonin, amylin, adrenomedullin, and intermedin, all of which signal through Class B G protein-coupled receptors composed of calcitonin receptor-like receptor (CLR) paired with receptor activity-modifying proteins (RAMPs). CGRP signals specifically through the CLR/RAMP1 complex. As the most potent endogenous vasodilator identified, CGRP is approximately 1,000-fold more potent than acetylcholine in relaxing vascular smooth muscle. It is densely expressed in sensory C-fibers and thinly myelinated A-delta fibers of the trigeminal ganglion, dorsal root ganglia, and perivascular sensory nerve terminals throughout the cardiovascular system. CGRP plays dual roles in the nervous system: as a sensory neurotransmitter in nociceptive signaling and as a potent vasoactive peptide in vascular regulation. The discovery that CGRP levels rise in jugular venous blood during migraine attacks (Goadsby et al., 1990) and that intravenous CGRP infusion provokes migraine-like headache in migraineurs (Lassen et al., 2002) established it as the central molecular target in migraine pathophysiology. This led to one of the most successful drug development programs in modern neurology: four monoclonal antibodies (erenumab/Aimovig targeting CLR/RAMP1; fremanezumab/Ajovy, galcanezumab/Emgality, and eptinezumab/Vyepti targeting the CGRP ligand) and three small-molecule CGRP receptor antagonists (gepants: ubrogepant/Ubrelvy, rimegepant/Nurtec, atogepant/Qulipta) have received FDA approval for migraine prevention or acute treatment between 2018 and 2022. Beyond migraine, CGRP has cardioprotective properties — it limits infarct size in ischemia-reperfusion injury models, promotes angiogenesis, and protects against heart failure progression. CGRP promotes wound healing by stimulating keratinocyte proliferation, enhancing dermal microvascular perfusion, and modulating local immune responses. In the gastrointestinal tract, CGRP contributes to mucosal protection and regulates gastric acid secretion. CGRP also plays roles in bone metabolism, lymphocyte regulation, and neurogenic inflammation. Despite extensive research, exogenous CGRP administration has not advanced to approved therapy due to its extremely short plasma half-life (~6.9 minutes), potent systemic vasodilation causing flushing and hypotension, and the advent of far more clinically practical anti-CGRP biologics. The peptide itself remains a critical research tool for understanding trigeminal neurovascular physiology, pain signaling, and cardiovascular regulation.

Frequently Asked Questions